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Abstract
Background: Gold nanoparticles (AuNPs) scatter light intensely at or near their surface plasmon wavelength
region. Using AuNPs coupled with dynamic light scattering (DLS) detection, we developed a facile nanoparticle
immunoassay for serum protein biomarker detection and analysis. A serum sample was first mixed with a citrate-
protected AuNP solution. Proteins from the serum were adsorbed to the AuNPs to form a protein corona on the
nanoparticle surface. An antibody solution was then added to the assay solution to analyze the target proteins of
interest that are present in the protein corona. The protein corona formation and the subsequent binding of
antibody to the target proteins in the protein corona were detected by DLS.
Results: Using this simple assay, we discovered multiple molecular aberrations associated with prostate cancer
from both mice and human blood serum samples. From the mice serum study, we observed difference in the size
of the protein corona and mouse IgG level between different mice groups (i.e., mice with aggressive or less
aggressive prostate cancer, and normal healthy controls). Furthermore, it was found from both the mice model
and the human serum sample study that the level of vascular endothelial growth factor (VEGF, a protein that is
associated with tumor angiogenesis) adsorbed to the AuNPs is decreased in cancer samples compared to non-
cancerous or less malignant cancer samples.
Conclusion: The molecular aberrations observed from this study may become new biomarkers for prostate cancer
detection. The nanoparticle immunoassay reported here can be used as a convenient and general tool to screen
and analyze serum proteins and to discover new biomarkers associated with cancer and other human diseases.
Background
Gold nanoparticles (AuNPs) scatter light intensely at or
near the surface plasmon resonance wavelength region
[1,2]. By combining the exceptional light scattering prop-
erty of AuNPs with dynamic light scattering, we recently
developed a new assay technique, NanoDLSay™,f o r
bimolecular detection and analysis [3-9]. Several other
groups have demonstrated the combined use of AuNPs
and DLS for quantitative estimation of nanoshells in
whole blood [10], highly sensitive detection of small bio-
logical molecules [11], toxic metal ions and explosives
[12-15]. Although DLS has not been traditionally used
for quantitative analysis, these recent studies by different
groups demonstrate that DLS can be used as a rather
reliable and sensitive technique for quantitative detection
and analysis of chemical and biological species.
DLS is an analytical technique that is used routinely for
particle size analysis [16]. Current DLS instruments can
detect particle size differences of 1-2 nm. Proteins are bio-
macromolecules with a hydrodynamic diameter of a few
nanometers: for example, the hydrodynamic diameter of a
bovine serum albumin is about 5-6 nm, and the hydrody-
namic diameter of an IgG molecule is around 7-10 nm.
When a layer of protein molecules are adsorbed or bound
specifically to a gold nanoparticle surface, the hydrody-
namic diameter of the nanoparticle-protein complex will
increase by as much as twice of the diameter of the pro-
tein [5,6]. The most unique capability of NanoDLSay™ is
that the assay can directly reveal the complexing status of
target proteins. In biological systems, a protein can exist in
three different forms as illustrated in Figure 1A: as
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any medium, provided the original work is properly cited.individual molecules; in complexes with other proteins or
biomolecules; and in aggregates. When a protein, protein
complex or aggregate is adsorbed or bound to AuNPs, this
will cause different size changes of the AuNP probes as
shown in Figure 1B, and such differences can be readily
detected by DLS [7-9]. In a previous study, we observed
that a prostate cancer biomarker, prostatic acid phospha-
tase (PAP) is substantially more complexed/aggregated in
prostate cancer tissue than tissues with normal and benign
conditions [8]. Normal and non-cancerous benign prostate
conditions can be distinguished from prostate cancer
based on the aggregation level of PAP in tissue samples.
Luchter-Wasylewska et al [17,18]. showed that at elevated
concentration, PAP tends to form oligomers and
aggregates. Our finding suggests for the first time that the
complexing/aggregation status of a protein instead of its
concentration change may potentially serve as a new type
of cancer biomarker. Using NanoDLSay™,w eh a v e
further discovered a new heteromeric protein complex
that is formed between epidermal growth factor receptor
(EGFR), Src and Stat3 in pancreatic cancer cells [9].
Recently, Dobrovolskaia et al. reported a systematic
study on human plasma protein adsorption to AuNPs
[19]. This work demonstrated that when citrate-protected
AuNPs are mixed with blood plasma, proteins from the
plasma adsorb to the AuNPs to form a “protein corona”.
They identified more than 60 proteins in the protein cor-
ona through a 2D PAGE gel isolation followed by a Mass
Figure 1 Illustration of the principle of NanoDLSay used for serum protein detection and analysis. (A) Illustration of proteins in different
forms. X refers to a target protein, while A, B, C, D, etc. refer to any known or unknown biomolecules that are complexed to the target protein
X. (B) Different particle size increase caused by the adsorption or binding of proteins in different forms. (C) The principle of the assay used in the
present study: In the first step of the assay, a serum sample is mixed with a citrate-protected AuNP solution. After the formation of a stable
protein corona around the AuNPs, an antibody specific to the interested target protein is added to the assay solution. When a target protein is
present on the nanoparticle surface, a further size increase of the nanoparticles can be observed through DLS measurement.
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raised the question: would there be any differences in the
size and composition of the protein corona between can-
cerous and non-cancerous serum samples. If so, such
molecular differences could potentially be used as a new
type of serum biomarker for cancer detection and diagno-
sis. To answer this question, we designed an assay format
as illustrated in Figure 1C based on the principle of
NanoDLSay™: A serum sample is first mixed with a
citrate-protected AuNP solution. After a protein corona is
formed on the nanoparticle surface, an antibody for a sus-
pected target protein is added to the assay solution. If the
target protein is present in the protein corona, the binding
of the antibody to the protein corona will cause a further
increase of the average nanoparticle size; otherwise, the
nanoparticle size will remain unchanged.
Using this simple assay, we analyzed the serum samples
collected from mice models and human donors with and
without prostate cancer. Indeed, we observed a number of
interesting molecular differences in the adsorbed protein
corona between cancer and non-cancerous samples.
Although we tested only a few target proteins in the pre-
sent study, it is easy to see that this assay may be used as a
general approach to analyze other target proteins and to
discover potential biomarkers for the detection, diagnosis
and prognosis of diseases.
Results
To have a complete understanding of our new assay and
the assay results, several important technical details
about the assay warrant explanation. First, the exception-
ally strong light scattering of AuNPs is essential for the
successful application of NanoDLSay™ for protein detec-
tion and analysis in blood serum samples. Blood serum is
a rather complicated biological fluid: it contains a large
amount of proteins, protein complexes, aggregates, col-
loidal particles and other biomacromolecules or bioma-
cromolecular assemblies that also scatter light intensely.
As an optical probe based on light scattering detection,
the scattered light intensity from the AuNPs must be
substantially stronger than the scattered light from the
biological samples to avoid the background interference
f r o mt h es a m p l em a t r i x .T h eA u N Ps o l u t i o nu s e di nt h e
present study has a hydrodynamic diameter of 90 nm
and at a concentration of 10 pM, it can generate a scat-
tered light intensity of around 400 kcps (kilo counts per
second) at a laser power of 0.04 mW. At this low laser
power, the scattered light from the serum samples added
to the AuNP solution is below the reliable detection limit
of the DLS instrument. This means that the nanoparticle
size increase observed from the assay solutions through
DLS analysis is solely caused by protein adsorption or
binding to the AuNPs. Other biomacromolecules or
colloidal particles from the serum samples that are not
attached to the AuNPs will not contribute to the DLS
signal. In the subsequent antibody screening of target
proteins, a high concentration of antibody is added to the
assay solution to bind with target proteins that remain in
solution or in the protein corona. Because the binding of
the antibody with the target proteins that remain in solu-
tion does not contribute to the size change of the AuNP
probes, there is no need to separate the AuNPs from the
assay solution to detect the target proteins that are
adsorbed to the AuNPs. Without a physical separation
step, the binding event that occurs on the AuNPs is iso-
lated from the rest of the assay solution and is selectively
detected by DLS measurement.
A second important detail is the relative ratio of the
AuNPs and proteins involved in the assay. The concentra-
tion of AuNP solution used in this study is 10 pM. The
total protein concentration of a human serum sample is
typically in the high 10s to 100 mg/mL range, correspond-
ing to a molar concentration in the 10s to 100 of μM
range. In the assay solution (2 μLs e r u mw a sm i x e dw i t h
40 μL AuNP solution), the total protein concentration is
10
5-10
6 times of the AuNPs. Even after 10-fold dilution,
the serum protein concentration is still about 10
4-10
5
times of the AuNP concentration. In other words, in the
assay solution, serum proteins are in substantially large
excess over the AuNPs. This large excess of serum pro-
teins versus AuNPs is to ensure a saturated adsorption of
serum proteins on the AuNPs. Only under the saturated
adsorption condition, the particle size increase of the assay
solution can be used to deduce the hydrodynamic dia-
meter of the proteins adsorbed on AuNPs.
A third important detail is the low concentration of
t h eA u N Ps o l u t i o nu s e di nt h ea s s a y ,1 0p M .T h i sl o w
concentration of AuNP was used to avoid nanoparticle
cluster formation caused by protein interaction. If sub-
stantial nanoparticle clusters are formed in the assay
solution, than the average particle size increase of the
assay solution cannot be used to deduce the protein
size. Initially, we used a 40 nm citrate-protected AuNP
with a concentration of 1 nM for the assay. When
serum samples were mixed with this AuNP solution,
significant nanoparticle clustering was observed, judging
from the broad and multi-model particle size distribu-
tion curves. By using the 90 nm AuNPs at a concentra-
tion of 10 pM, the particle size distribution curves of all
assay solutions remained narrow and monodispersed
(polydispersity index around or below 0.2-0.3), indicat-
ing that nanoparticle cluster formation during the assay
was minimized. In this case, the observed particle size
increase of the assay solution can be correlated to the
size information of the proteins or protein complexes
that were adsorbed to the AuNPs.
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prostate tumor and healthy controls
Three orthotopically injected mouse models were pre-
pared for this study: one with a fast growing prostate
cancer cell line PC3; one with a slow growing tumor
cell line LnCaP; and a third group of mice injected with
PBS saline solution as control (See the Additional File 1
for details on mice model development, tumor examina-
tion and serum sample collection) [20-22]. The size and
the weight of each tumor are summarized in Table 1.
As expected, mice injected with PC3 cells grew substan-
tially larger tumors (in the gram range) than those
injected with LnCaP cells (in the 10s to 100 mg range).
No tumor was found in the prostate of control mice.
The average weight ratio of tumor over the body weight
is approximately 5% for the PC3 mice, and less than
0.3% for the LnCaP mice. These ratios would corre-
spond to a tumor weight of 2.5 Kg and 150 g respec-
tively in a human patient with a body weight of 50 Kg.
We first analyzed the size change of the AuNPs caused
by serum protein adsorption. From these analyses, several
differences amongst the PC3 mice, LnCaP mice and
healthy controls were observed. First, the average particle
size increase of the healthy control group was 75 nm, sig-
nificantly higher than the PC3 mice that had an average
particle size increase of 24 nm (Figure 2A). The average
particle size increase for LnCaP mice was 43 nm. It was
also noticed that within the healthy control or LnCaP
mice group, there were substantial variations between
individual mice: the particle size increase varied from
20-110 nm for the LnCaP mice, and 40-120 nm for the
healthy control mice. As to the PC3 mice, the particle
size increase was uniformly low: in the range of
20-25 nm. When the serum samples were first diluted
10-fold, the average particle size increase caused by pro-
tein adsorption decreased to 18 nm for the healthy con-
trol group, and 15 nm for both the PC3 and LnCaP mice
(Figure 2B). These particle size increases were reached
after 2-3 minutes following sample-AuNP mixing, and
remained unchanged thereafter.
Target protein detection and analysis from mouse serum-
adsorbed AuNPs
A f t e rs e r u mp r o t e i na d s o r p t i o no nt h eA u N P s ,w et h e n
analyzed two target proteins in the protein corona by
adding corresponding antibodies to the assay solution:
one is IgG and another one is vascular endothelial growth
factor (VEGF). IgG is one of the most abundant serum
proteins, with a concentration in the 10s mg/mL range. It
is reasonable to believe that IgG should be found in the
serum protein corona. The target protein analysis was
conducted using 10-fold diluted serum samples instead
of the undiluted serum samples: because the protein cor-
ona formed on the AuNPs has a similar size of 15-18 nm
for all three mice groups, the size increase observed from
anti-IgG assay can be used directly to compare the IgG
levels of different samples.
Data shown in Figure 3A is the measured particle size
difference before and after the addition of anti-mouse
IgG antibody to the serum-AuNP mixture solution. The
particle size was increased for all mice serum samples,
however, LnCaP mice appeared to have a higher level of
IgG in the protein corona than the other two groups.
Furthermore, there were significant variations in the IgG
level of different mice within the same group, particu-
larly in the LnCaP mice group.
Table 1 Information on the mice models used in the current study
Mice No. Cell Line Tumor weight(g) Tumor Volume (mm
3) Body weight(g) Collection date
C 1 n/a 0 0 37.86 5 weeks
C 2 n/a 0 0 39.65 5 weeks
C 3 n/a 0 0 26.77 5 weeks
C 4 n/a 0 0 24.08 5 weeks
C 5 n/a 0 0 28.83 5 weeks
M 1 PC3 1.97 1798 37.71 4 weeks
M 2 PC3 2.37 1280 38.16 4 weeks
M 6 PC3 0.95 1088 37.75 4 weeks
M 7 PC3 0.89 1488 32.13 4 weeks
M 10 PC3 2.92 1987 40.87 4 weeks
M 225 LnCap 0.102 169 31.33 5 weeks
M 999 LnCap 0.072 212 31.68 5 weeks
M 211 LnCap 0.087 365 31.17 5 weeks
M 213 LnCap 0.068 t.s.t.m* 29.31 5 weeks
M 216 LnCap 0.033 t.s.t.m 29.29 5 weeks
M 220 LnCap 0.043 t.s.t.m 33.38 5 weeks
*t.s.t.m.: too small to measure.
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biomarker that is associated with almost all types of cancer
due to its essential role in tumor angiogenesis [23-25].
Naturally, we selected VEGF as a target protein to analyze
in this study. Rabbit polyclonal anti-VEGF (ab9570) was
used for this assay. Figure 3B is the particle size increase
of the assay solution after anti-VEGF antibody addition.
To our surprise, the healthy control mice showed much
larger particle size increase than the tumor-bearing mice:
the average particle size increase was about 18 nm for
healthy control mice and the average particle size increase
was only 6 nm for tumor-bearing mice. Furthermore, the
particle size increase varied significantly from 8 nm to
more than 30 nm among the individual healthy control
mice, while the particle size increase varied only from 4 to
9 nm for tumor-bearing mice.
Human serum protein adsorption to AuNPs and VEGF
analysis
Three groups of human serum samples were included in
this study: normal healthy donors (n = 15); patients
diagnosed with benign prostate hyperplasia (BPH, n =
10); and patients diagnosed with prostate cancer with
stages from T1c to T3b (n = 25). A list of the sources
and clinical information can be found in the Additional
File 1, Table 1S. It should be mentioned here that the
healthy donors were asymptomatic, but not clinically
confirmed as being cancer-free or without BPH.
We first conducted the analysis of human serum
adsorption to the AuNPs. Assaying undiluted human
serum samples, no difference between the three groups
of human serum samples was observed: the average par-
ticle size increase for cancer and the normal/BPH group
Figure 2 Mouse serum protein adsorption study on AuNPs. (A) Undiluted serum; (B) 10-fold diluted serum in 10 mM PB. Particle size
increase shown in the graph is the difference between the measured particle size at 8 min (for undiluted serum samples), or 5 min (for diluted
serum samples) and the particle size at 1 min after mixing 2 μL of serum with 40 μL of AuNP solution. Error bars are standard deviations from
two replicate assays.
Figure 3 Mouse IgG (A) and VEGF (B) assay of 10-fold diluted mouse serum adsorbed to AuNPs. The particle size change presented in
both graphs is the difference between the size measured at 5 min after antibody addition and the size just before antibody addition.
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However, there were significant differences between
individual samples, suggesting that each individual has
different serum molecular profiles. When the serum was
diluted 10-fold, the adsorption of all samples (a total of
50 samples from the three groups), caused a uniform
particle size increase of around 20-25 nm. Similar to the
diluted mice serum protein adsorption study, this size
increase was observed within one or two minutes of
incubation and remained unchanged thereafter.
For VEGF analysis, two anti-VEGF antibodies were
used in this study: ab9570 and ab39250. VEGF has sev-
eral isoforms that are known to play different roles in
tumor angiogenesis: VEGF121, 145, 165, 183, 189 and
206 (the number represents the amino acid length of the
protein) [26-28]. While ab9570 is specific to VEGF121
and 165, ab39250 is reactive to VEGF121, 165 and 189
[29]. The results shown in Figure 4A and B were
obtained from using ab9570 anti-VEGF in the assay, and
the results in Figure 4C were obtained from using
ab39250 anti-VEGF in the assay.
The VEGF assay was first conducted on the 10-fold
diluted human serum samples (Figure 4A) using the
ab9570 antibody. Although the particle size change was
small, nevertheless, there was a clear difference between
the prostate cancer and non-cancerous group. While the
average particle size change for the normal and BPH
group was about 2 nm, the size change was only ~0.5 nm
for the 25 prostate cancer samples. T-test analysis
revealed a p-value of 0.001 for this assay. Hence, the dif-
ference observed from the cancer and non-cancer group
is statistically significant. Furthermore, it was noticed
that the samples that exhibited a relatively large particle
size increase in the cancer group were all from patients
with very early stage cancer (marked in Figure 4A).
Among the six samples highlighted, four were from T1c
stage cancer and two from T2 stage cancer. Among the
two T2 stage samples, one was from a patient 82 years
old (most other donors were below 75 years). Another
sample, although it was staged as a T2 stage cancer
according to the TNM system, it was assigned as a group
stage I cancer clinically, indicating that it was a very early
stage cancer. By excluding these six early stage cancer
samples, the average particle size change of the cancer
group became zero. Notably, among all of the cancer
samples tested in this study, none of the relatively
advanced cancer samples with a stage from T2c to T3b
(total 7, data marked in cyan) showed a particle size
increase of more than 1 nm.
This same trend was also observed in the undiluted
serum samples (Figure 4B) using the same antibody as
used in Figure 4A. While the average particle size
increased by 24 nm for the non-cancerous group, the aver-
age particle size increased only by 7 nm for the prostate
cancer samples. T-test analysis of this set of assay data
gave a p-value of 0.001. Compared to the 10-fold diluted
serum samples, the VEGF assay of undiluted serum
resulted in a substantial particle size increase, indicating
that without dilution, more VEGF proteins were detected
from the AuNP surface.
Although the VEGF assay of both diluted and undiluted
samples revealed statistically significant differences
between cancerous and non-cancerous samples, there are
some issues with the above assays. For the diluted serum
samples, the particle size increase caused by the anti-
VEGF addition is rather small and too close to the experi-
mental error of the DLS measurement, which is 1-2 nm
for the AuNP probe solution. For the undiluted serum
samples, the initial particle size after serum protein corona
formation varies significantly from one sample to another
as seen from Additional file 1, Figure S2. This makes it dif-
ficult to compare the nanoparticle size increase caused by
the anti-VEGF antibody addition. It also makes it difficult
to use such particle size increases to evaluate the different
levels of VEGF in the protein corona. In an attempt to
optimize the assay, we used a different anti-VEGF anti-
body for the analysis. Figure 4C is the VEGF assay results
of 10-fold diluted human serum samples obtained using
the ab39250 antibody. The same trend was observed as in
the other assay using the ab9570 antibody. Non-cancerous
serum samples showed a higher level of VEGF in the
serum protein corona adsorbed on AuNPs than the cancer
group samples. The average particle size increase was
16 nm for the non-cancer group and 9 nm for the cancer
group samples. The p-value for this assay is 0.009, indicat-
ing that the observed difference is statistically significant.
For comparison, we also analyzed an established pros-
tate cancer biomarker, prostatic acid phosphatase (PAP)
[30], in this study. The assay results (Figure 5) showed no
difference between the cancer and non-cancer samples:
the average particle size increase observed from the nor-
mal and BPH group was almost the same as the cancer
group. The p-value of this assay was 0.73. Even though
PAP is known as a biomarker for prostate cancer, it is not
a biomarker for early stage prostate cancer detection. It
only shows a significant difference when prostate cancer
has advanced into the metastasized stage [30]. None of the
samples tested in our study is from a metastasized prostate
cancer. Therefore, it is not surprising that we did not
observe difference between cancer and non-cancer sam-
ples in PAP assay.
Specificity study of the VEGF assay of human serum
samples
To confirm that the particle size increase after anti-VEGF
antibody addition to the assay solution is indeed due to
the specific binding between the antibody and VEGF pro-
tein adsorbed on AuNPs, we conducted two control
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cific isotype control, Rabbit IgG, to repeat the assay. The
results are included in Figure 4C along with the anti-
VEGF assay results for comparison. It is clear that the
particle size increase caused by anti-VEGF addition was
substantially larger than the isotype control antibody: 16
nm for the non-cancer group and 9 nm for the cancer
group. The average particle size increase caused by
Rabbit IgG addition was only around 2.7 nm. More
importantly, there is no difference between the average
particle size increase of the cancer versus non-cancerous
group, confirming that Rabbit IgG binds only weakly and
non-specifically to the serum protein-adsorbed AuNPs.
In a second control experiment, we chose 5 diluted
serum samples (four from the normal group and one
from the cancer group) that show the highest particle
Figure 4 VEGF assay of human serum samples and control study. (A) 10-fold diluted and (B) undiluted human serum samples using anti-
VEGF antibody (ab9570). The particle size change presented in both graphs is the difference between the size measured at 5 min after antibody
addition and the size measured just before antibody addition. (C) 10-fold diluted human serum samples using anti-VEGF antibody (ab39250). The
particle size change presented in the graph is the difference between the size measured before antibody addition and the size measured at 9
min after antibody addition. Also shown in (C) is the particle increase of the assay solution by adding a Rabbit IgG isotype control to the assay
solution (data in blue colored columns). The particle size change presented in the graph is the difference between the size measured before
antibody addition and the size measured at 9 min after antibody addition. Data presented in (A) and (B) were obtained using Malvern ZS90 DLS
system; while data presented in (C) were obtained from Nano Discovery NDS-1200 system. Error bar shown in this graph is the standard
deviation of two replicate assays.
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Figure 4C. We then added an equal amount of Rabbit
IgG and anti-VEGF (ab39250) to an equivalent volume
of the diluted serum samples (i.e. 5 μL of 10-fold diluted
serum with 5 μL of Rabbit IgG or anti-VEGF at 1 mg/
mL) and incubated the mixed solution for 30 minutes at
r.t. The treated samples (4 μL) were then mixed with
AuNP solution (40 μL), and the particle size increase of
the assay solution was analyzed. Figure 6 is the average
particle size increase observed from the untreated
diluted serum, Rabbit IgG-treated diluted serum, and
anti-VEGF-treated diluted serum samples, respectively.
Without the pretreatment of any antibody, the average
particle size of the assay solutions increased by about
20-25 nm, the same as we observed throughout the
study. When the serum samples were pretreated with
the non-specific Rabbit IgG isotype control, the particle
size increase was about the same as that without anti-
body addition. This suggests that Rabbit IgG exhibited
minimum binding to the serum proteins, and had little
effect on the size of the “protein corona” formed on the
AuNP surface. In contrast to the Rabbit IgG isotype
Figure 5 PAP assay of 10-fold diluted human serum samples. Normal and BPH samples were randomly selected from the total 25 samples.
Cancer samples used for this assay are those with a stage of T2c or above. The particle size change is the difference between the size measured
at 5 min after antibody addition and the size measured just before antibody addition.
Figure 6 Antibody-treated and untreated serum adsorption study to AuNP. Three types of samples were analyzed: 10-fold diluted human
serum; Rabbit IgG isotype control-treated 10-fold diluted human serum; and anti-VEGF (ab39250) treated 10-fold diluted human serum samples.
Five samples that show the highest particle size increase from the anti-VEGF assay as shown in Figure 4C were chosen for this study.
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caused a significantly larger particle size increase of
more than 50 nm. This result confirmed the specific
binding between anti-VEGF and VEGF proteins in the
serum samples.
Discussion
This study has led to several very interesting findings. Of
all the results, the first most interesting finding is that
there is a significant difference in the “size” of the serum
protein corona formed on the AuNPs surface between
cancerous and non-cancerous, or less malignant tumor-
bearing mice models. Although the exact molecular
mechanism behind these differences is unclear, we cau-
tiously propose that the different protein corona sizes are
reflective of the different “complexing level” of serum pro-
teins in the samples, not due to unsaturated coverage of
proteins on the AuNPs. As explained at the beginning of
the “Results” section, even after the serum is diluted 10-
times, the total serum protein concentration is still 10
4-
10
5 times higher than the AuNP concentration. In pre-
vious work we have conducted, we found that most IgG
molecules will form a complete coverage on the AuNPs in
just one or two minutes at a concentration between 0.1-1
mg/mL. Even in the 10-fold diluted serum samples, the
IgG concentration is still at the 1 mg/mL range. IgG mole-
cules alone in the diluted serum samples should be able to
form a complete coverage on the AuNPs surface. The sub-
stantially smaller protein corona found from PC3 mice
compared to the other two groups suggests that when
tumor progresses, there may be some chemicals released
from the tumor cells that have led to the disruption of
serum protein complexing. The relative ratio of tumor ver-
sus body weight of PC3 mice (5%) is enormous compared
to LnCaP mice (0.3%) and typical human cancer patients.
Because of the large tumor grown in PC3 mice, the mole-
cular change is manifest and all PC3 mice serum samples
exhibit a uniformly small protein corona in the assay.
In addition to the difference between different mice
groups, it was also noticed that the protein corona size
varies substantially between individual mice within the
same group, particularly in the LnCaP mice and healthy
control group. All mice were the same type and same age
(the mice were randomized into the three groups before
experiments), and were kept at the same environment
under the same diet during the experiment. The difference
observed within the same mice group can only be attribu-
ted to the different biological responses and physical con-
ditions of individual mice. Cancer is well known for its
heterogeneity and for its extremely complicated and
diverse molecular mechanisms. The molecular differences
observed from our study appear to corroborate with this
well known fact and suggest the need of personalized
medicine for cancer treatment.
From the human serum study, we did not observe signif-
icant difference in the serum protein corona size between
cancer and non-cancer groups. All human cancer serum
samples used in this study are from a relatively early stage
prostate cancer of T1c to T3b, and the cancer has not yet
metastasized. Because of the relatively small tumor size,
the molecular change in the serum caused by cancer is not
as obvious as that found from the mice model study.
The second most significant finding observed from this
study is the different VEGF levels that were found in the
mice and human serum samples. The VEGF assay of
both human and mouse serum samples revealed that in
the protein corona adsorbed to AuNPs, there is a
decreased level of VEGF in the cancerous samples as
compared to the samples from healthy and benign condi-
tions. This finding appears to be contradictory to what is
generally believed about VEGF: that the level of VEGF is
often elevated in the blood of cancer patients [31-33].
We attribute this discrepancy to the following possible
reason. VEGF is not an abundant protein in the serum.
Its concentration in blood is commonly reported to be in
the high pg/mL to low ng/mL range [32,33]. This con-
centration is 10
6-10
9 times lower than the abundant
serum proteins such as IgG and serum albumin, which
occur in a concentration range of 10s mg/mL. Upon mix-
ing with AuNPs, abundant proteins such as IgG and
serum albumin will be quickly adsorbed to AuNPs. It is
most likely that the VEGFs detected in the assay are
adsorbed to the AuNPs through a more abundant “car-
rier” protein or other types of biomolecules. In other
words, the VEGF detected from our assay is a serum pro-
tein-complexed form of VEGF, not the typical individual
VEGF proteins as detected using other existing immu-
noassay methods.
In addition to the above two most important findings,
the IgG assay of mouse serum samples is also very inter-
esting. Mice with small tumor grown from LnCaP cells
showed substantially higher IgG level than normal healthy
mice and mice with large tumor grown from PC3 cells
(Figure 3A). This difference suggests that mice responded
differently to the orthotopic injection of LnCaP and PC3
cells. It appears that the injection of LnCaP cells may have
triggered certain immunogenic response from the mice,
and such immunogenic response has slowed down the
tumor growth. The significant variation of IgG level within
the same mice group is again most likely due to the differ-
ent biological responses and physical conditions of indivi-
dual mice.
Conclusions
In summary, we reported here a facile nanoparticle-based
immunoassay for serum protein analysis. Serum is a
complex biological fluid containing trace and abundant
proteins, macromolecular complexes and microparticles
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technique-based assays. Hereto, by taking advantage of
the exceptionally strong scattering intensity of gold nano-
particles, we were successful in overcoming this challenge
and developed a homogeneous solution assay for serum
protein analysis. Using this simple assay, we observed
multiple molecular differences between prostate cancer
and non-cancerous samples. Analysis of samples from
both mouse models and human subjects revealed that
the amount of AuNP-adsorbed VEGF is decreased in
cancer samples. We are currently conducting further
extensive studies to understand the mechanistic origins
of these molecular changes. By screening other proteins
or biomolecular targets adsorbed to the AuNPs, it is
likely that additional proteins or biomolecular profiles
that are unique to disease states will be discovered. The
assay method reported here can potentially become a
general new approach for cancer biomarker discovery
and research.
Methods
Chemical and Biochemicals
Gold nanoparticle (AuNPs) with a diameter of 90 nm as
measured by DLS (15708-9) was purchased from Ted
Pella Inc. (Redding, CA). The concentration of this gold
nanoparticle was 10 pM. All the antibodies used in the
present study were from Abcam (Cambridge, MA): rabbit
polyclonal anti-mouse IgG (ab6708, lot 951580, 2.0 mg/
mL); rabbit polyclonal anti-VEGF (ab9570, lot 942538,
0.5 mg/mL); rabbit polyclonal anti-VEGF (ab39250, lot
GR22131-1, 1 mg/mL); rabbit polyclonal anti-prostatic
acid phosphatase (PAP) (ab97517, lot gr742-1, 0.8 mg/
mL); and rabbit IgG isotype control (ab37415, lot 905012,
5 mg/mL).
Animal and human serum samples
Mouse serum samples used in this study were obtained
from mice models prepared according to procedures
described in the Additional File 1. This study was
approved by University of Central Florida Institutional
Animal Care and Usage Committee (IACUC) under the
protocol number of 09-26. Specific pathogen-free condi-
tions and facilities, approved by the American Association
for Accreditation of Laboratory Animal Care (AAALAC)
and compliant with the regulations and standards of the
United States Department of Agriculture, the United
States Department of Health and Human Services and the
NIH, were used to house and maintain all mice.
Human serum samples from male donors diagnosed
with prostate cancer or benign prostate hyperplasia, and
healthy controls were obtained from MD Anderson Can-
cer Center Orlando (MDACCO) and Asterand Solutions
(solutions.asterand.com). The collection and use of
human serum samples for the project was approved by
MDACCO IRB committee under the protocol number of
09.061.09. Human serum samples from Asterand Solu-
tions were de-identified archived samples. No IRB
approval was required for using these samples. A list of
detailed information on the source and clinical data
of human serum samples can be found in the Additional
file 1, Table S1.
DLS measurements
The DLS measurements were conducted using two differ-
ent instruments: The first one is a Zetasizer Nano ZS90
DLS system equipped with a red laser (633 nm) and an
Avalanche photodiode detector (APD) (Malvern Instru-
ments Ltd, England). The second instrument is an auto-
matic NDS-1200 DLS system from Nano Discovery Inc.
The detection system of NDS-1200 is similar to the ZS90
system. Additionally, NDS-1200 is equipped with a 12
sample holder-carousel that allows automatic measure-
ment of 12 samples within 5-6 minutes. Data presented
from Figure 2 to Figure 4A and B, and Figure 5 were
obtained from ZS90 system, and data presented in Figure
4C and Figure 6 were from NDS-1200 system. The aver-
a g ep a r t i c l es i z eo ft h es o l u t i o nw a so b t a i n e du s i n ga
Cumulant method for both systems.
Assay methods
In the serum adsorption study, 40 μL of AuNP solution
was mixed with 2 μL of undiluted or 10-fold diluted
serum sample in 10 mM phosphate buffer (PB). The parti-
cle size of the mixed solution was measured three times at
1, 5, and 8 min of incubation for the undiluted serum
samples, and twice at 1 and 5 min of incubation for the
diluted serum samples. Data presented in Figure 2A are
the particle size difference measured at 8 min and 1 min
of incubation; and data presented in Figure 2B are the par-
ticle size difference measured at 5 min and 1 min of incu-
bation. For both undiluted and diluted mouse serum
protein adsorption study, each assay was repeated twice
and the error bar presented in Figure 2A and 2B are the
standard deviations. Results of serum protein adsorption
study of undiluted human serum samples are presented in
Additional file 1, Figure S2. The cancer group samples
were assayed twice and the error bars are standard devia-
tions. When the serum was diluted 10 fold, the adsorption
of all diluted human serum samples, observed from total
50 samples from the three different groups, caused a uni-
form particle size increase of around 20-25 nm.
For target protein assays (IgG, VEGF or PAP), an appro-
priate amount of antibody solution was added to the assay
solution following the serum adsorption to AuNPs. The
particle size change was then measured again by DLS after
5 minutes of incubation. The amount of the antibody solu-
tion added to the serum-AuNP mixture solution was: 1 μL
for anti-mouse IgG; 2 μL for anti-VEGF; and 2 μLf o r
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Page 10 of 12anti-PAP. Different volumes of antibody solution were
used in different assays to ensure that the amount of the
antibody used for each assay is about the same. For mouse
IgG assay, 6 samples randomly selected from the three
sample groups were assayed twice and the error bars
shown in Figure 2A are standard deviations.
All incubation and particle size analysis were done at
ambient temperature of 25°C.
Statistical Analysis
We applied T-tests for comparison of means of human
serum sample assay results. These tests assume that the
data are normally distributed and that individuals in differ-
ent groups are independent. We tested the null hypothesis
that the means of two groups (normal and BPH were
combined as one group and prostate cancer as the second
group) are equal versus the alternative that they are not
equal, with and without the assumption of equal variances
in the two groups. Statistical analysis resulted in p-values
for each of the individual tests. Small p-values can be
viewed as strong evidence that the differences between the
two sample groups are statistically significant.
Additional material
Additional file 1: Experimental details on animal model
development and sample collection; a list of human serum samples
used in the present study with source and clinical information; and
the results of human serum adsorption to AuNPs can be found in
Additional File 1.
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